# Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

> **NCT03611010** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Hypercholesterolemia
- Dyslipidemias

## Interventions

- **DRUG:** Atorvastatin injection

## Key facts

- **NCT ID:** NCT03611010
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-07
- **Primary completion:** 2020-02-17
- **Final completion:** 2020-02-24
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03611010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03611010, "Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03611010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*